Announcing the 2025 LCRF | Boehringer Ingelheim Early Career Investigator Awards: three awardees each received a $250k grant for projects focused on HER2-driven lung cancer. Read more about these scientists and the focus of their studies. https://t.co/F10TCUuMBI
Grateful to have completed my MHS in Clinical Investigation at @YaleMed 🎓
Thankful to my mentors at @YaleDigestive, colleagues, family, and friends for their support throughout this journey ✨ excited for what comes next!
#MHS#Yale#MedTwitter
A meaningful milestone in my training. Grateful for the opportunity to learn from exceptional mentors and colleagues @YaleMed@YaleDigestive and for the experiences that have shaped my growth as a clinician and investigator 🎓
We're thrilled to officially announce the 2026 class of Conquer Cancer Grants and Awards recipients! 🔬 These grants empower the next generation of physician-scientists to turn innovative ideas into clinical breakthroughs. Congratulations to the new class—see you in Chicago for #ASCO26!
Full list of recipients here: https://t.co/Ltov9bTGYi
#ResearchConquersCancer #ConquerCancer @ASCO
Thank you fellows, faculty, and OncLive for an outstanding day of learning, collaboration, and networking. Inspiring discussions, new connections, and a shared commitment to advancing care. The future is bright! @OncLive@StephenVLiu@drshieldsmd@PatelOncology
Research presented by Mariana Do Carmo @yalepathology shows tumor suppressor gene loss plays a major role in how EGFR-mutant #lungcancer grows and responds to therapy. Certain gene losses can accelerate tumor growth or drive resistance to EGFR inhibitors. #AACR26@AACR@SmilowCancer@OncoAlert@StockhammerPaul
Ross Camidge’s incredible presentation from #TTLC26 is now available online. Anyone who deals with cancer in any capacity should watch it. You might cry (I did) but it’s worth it. Thank you @IASLC for making the presentation publicly available.
https://t.co/GIn7KqMAZ5
Do HER2 mutant #NSCLC tumors progressing on T DXd lose HER2 dependence?
No. Resistance is mainly driven by payload related mechanisms such as SLFN11 loss or ABCC1 gain, or impaired antibody binding due to domain IV mutations, rather than loss of the HER2 driver.
HER2 signaling persists, and tumors retain sensitivity to #HER2 TKIs (zongertinib/poziotinib). Progression on #TDXd opens a rational path to TKIs
https://t.co/YCVPBankzU @OncoAlert @AndresFCardonaZ
Results from part 1 of phase Ib DESTINY-Lung03: trastuzumab deruxtecan (T-DXd, HER2 ADC) in HER2 overexpressing NSCLC @JTOonline. Monotherapy (n=36) RR 44.4% with serious AEs in 16.7%. Combo with durvalumab + carbo (n=24) RR 37.5%, serious AEs in 37.5%.
https://t.co/Ew9Kttcu5s